As the focus of intense enforcement scrutiny over the past decade, multinational pharmaceutical companies have developed sophisticated and robust investigations programs for anti-corruption issues as well as other fraud and compliance risks. Lisa LeCointe-Cephas, the head of global investigations at Merck, began her investigations career in life sciences as outside counsel before moving to in-house positions, first at Bristol-Myers Squibb and then Merck. The Anti-Corruption Report spoke with LeCointe-Cephas about overcoming the technological, cultural and logistical challenges of running a global investigations program in a highly regulated, highly global industry. See “Investigation Strategies During Social Distancing” (Apr. 1, 2020).